Actavis Announces Daytrana® Patent Challenge Settlement

           Actavis Announces Daytrana® Patent Challenge Settlement  PR Newswire  DUBLIN, March 19, 2014  DUBLIN, March 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana^® (Methylphenidate Transdermal System). Daytrana^® is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.  Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing license to market its generic Daytrana^® beginning on Sept. 1, 2015, or earlier under certain circumstances. Other details of the settlement were not disclosed.  Launch of Actavis' product is contingent upon Actavis receiving final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for generic Daytrana^®. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Daytrana^® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.  For the 12 months ending December 31, 2013, Daytrana^® had total U.S. sales of approximately $98 million, according to IMS Health data.  About Actavis Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.  Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries. The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.  For press release and other company information, visit Actavis' Web site at http://www.actavis.com.  Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing information as of the date of this release. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actual results may differ materially from Actavis' current expectations depending upon a number of factors, risks and uncertainties affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities or agencies; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Actavis' and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plc's Annual Report on Form 10-K for the year ended December 31, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.  Daytrana^® is a registered trademark of Noven Therapeutics, LLC.  CONTACTS: Investors:           Lisa DeFrancesco           (862) 261-7152           Media:           Charlie Mayr           (862) 261-8030           David Belian           (862) 261-8141    Actavis plc logo  Logo- http://photos.prnewswire.com/prnh/20130124/NY47381LOGO  SOURCE Actavis plc  Website: http://www.actavis.com  
Press spacebar to pause and continue. Press esc to stop.